Adis Summary of Research: Extended ‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder

AbstractIn patients with attention deficit hyperactivity disorder (ADHD), norepinephrine reuptake inhibitors like atomoxetine may show mild effectiveness in addressing both inattention and hyperactivity/impulsivity. The relative efficacy of branded extended-release viloxazine (viloxazine ER) compared to generic atomoxetine remains unknown. This Adis Summary of Research summarizes the efficacy and tolerability of a voluntary switch from atomoxetine to viloxazine ER, prompted by adverse events or inadequate response, based on a retrospective chart review conducted in the USA. The switch improved ADHD symptoms and tolerability.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research